Copeptin, the 39-amino-acid C-terminal portion of provasopressin, has been shown to be an independent predictor for adverse events following STEMI (ST elevation myocardial infarction). We hypothesized that plasma copeptin was an independent predictor for adverse outcomes following acute NSTEMI (non-STEMI) and evaluated whether copeptin added prognostic information to the GRACE (Global Registry of Acute Coronary Events) score compared with NT-proBNP (Nterminal pro-B-type natriuretic peptide). Plasma copeptin and NT-proBNP were measured in 754 consecutive patients admitted to the hospital with chest pain and diagnosed as having NSTEMI in this prospective observational study. The end point was all-cause mortality at 6 months. Upper median levels of copeptin were strongly associated with all-cause mortality at 6 months. Copeptin was a significant predictor of time to mortality {HR (hazard ratio), 5.98 [95 % CI (confidence interval, 3.75-9.53]; P < 0.0005} in univariate analysis and remained a significant predictor in multivariate analysis [HR, 3.03 (05 % CI,; P = 0.009]. There were no significant differences between the area under ROC (receiver operating characteristic) curves of copeptin, NT-proBNP and the GRACE score. Copeptin improved accuracy of risk classification when used in combination with the GRACE score as determined by net reclassification improvement, whereas NT-proBNP did not. The relative utility of the GRACE score was increased more by copeptin than by NT-proBNP over a wide range of risks. Plasma copeptin is elevated after NSTEMI, and higher levels are associated with worse outcomes. Copeptin used in conjunction with the GRACE score improves risk stratification enabling more accurate identification of high-risk individuals.
INTRODUCTION
Recent guidelines recommend risk stratification of all patients following admission with NSTEMI {non-STEMI [ST elevation MI (myocardial infarction)]} in order to identify those individuals at maximum risk of adverse outcomes who may benefit from early aggressive therapy [1] . Currently, clinical risk assessment tools such as the TIMI (Thrombolysis in Myocardial Infarction) [2] and GRACE (Global Registry of Acute Coronary Events) [3] scores are the most commonly used method of risk stratification, although more recently, plasma biomarkers have emerged as a potentially alternative or complementary technique [4] .
Copeptin is the 39-amino-acid C-terminal portion of provasopressin, the precursor of AVP (arginine vasopressin) [5] . Copeptin has the advantages of a longer plasma half-life and reduced propensity for protein binding compared with AVP making its measurement more accurate [6] . Copeptin has recently been demonstrated to be an independent predictor for adverse events following STEMI [7] .
We hypothesized that plasma copeptin is an independent predictor for adverse outcomes following acute NSTEMI and further sought to evaluate whether copeptin provided additional prognostic information to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the GRACE score, established risk stratification markers.
The present study presents a post hoc analysis of a subset of patients with NSTEMI recruited to the original LAMP (Leicester Acute Myocardial Infarction Peptide) cohort study of patients with acute MI supplemented with a new cohort of NSTEMI patients.
MATERIALS AND METHODS

Study population
We analysed patients admitted to the Leicester Royal Infirmary and Glenfield Hospital, Leicester, with acute MI. The population for this LAMP II study was comprised of patients recruited as follows: (i) 239 NSTEMI patients who were included in the original LAMP study, which included both NSTEMI and STEMI patients, who were recruited between March 2000 and July 2005; and (ii) a new group of 515 NSTEMI patients who were recruited between August 2005 and April 2007. As a control group, plasma copeptin and NT-proBNP were also measured in 82 healthy males over 65 and 41 females over 70 years of age.
The present study abided by the Declaration of Helsinki and was approved by the local ethics committee. Written informed consent was obtained from all the patients. Acute NSTEMI was diagnosed if the patient described a history of cardiac sounding chest pain lasting greater than 20 min not associated with ST segment elevation with a plasma CK-MB (creatine kinase-MB) level twice the upper limit of normal or cardiac troponin I level >0.1 ng/ml [8] . NSTEMI was confirmed in all patients prior to inclusion. The Centaur cTnI Ultra immunoassay (Siemens Healthcare Diagnostics) was used to measure troponin I, which has a CV (coefficient of variation) of 10 % at 0.03 ng/ml with a 99th percentile of 0.04 ng/ml. We chose this cut-off to ensure patients had a definite diagnosis of NSTEMI.
Patients with known malignancy or surgery in the previous month were excluded. The eGFR (estimated glomerular filtration rate) of the study patients was calculated from the simplified formula derived from the MDRD (Modification of Diet and Renal Disease) study validated in patients with HF (heart failure) [9] .
Plasma samples
Blood samples were taken within 24 h of admission (at a median time of 25.75 h following onset of chest pain) for determination of plasma levels of copeptin and NTproBNP. After 15 min of bed rest, 20 ml of blood was collected into tubes containing EDTA and aprotinin. All plasma was stored at − 70
• C until assayed in a blinded fashion in a single batch.
Copeptin assay
Copeptin was detected with a novel commercial assay. Briefly, tubes were coated with a purified sheep polyclonal antibody raised against a peptide that represented amino acids 132-147 of preproAVP. A purified sheep polyclonal antibody raised against a peptide representing amino acids 149-164 of preproAVP was labelled with methylacridinium N-hydroxysuccinimide ester (InVent) and was used as tracer. Dilutions of a peptide representing amino acids 132-164 of preproAVP in normal horse serum served as standards. The immunoassay was performed by incubating 50 μl of samples/standards and 200 μl of tracer in coated tubes for 2 h at room temperature. Tubes were washed four times with 1 ml of wash solution (BRAHMS AG), and bound chemiluminescence was measured with an LB952T luminometer (Berthold). The assay limit of detection was 0.4 pmol/l, with functional assay sensitivity <1 pmol/l. The inter-assay CV was 10 % at 3 pmol/l and <7 % for values >10 pmol/l.
NT-proBNP assay
The NT-proBNP assay used was based on a noncompetitive assay [10] . Sheep antibodies were raised to the N-terminal of human NT-proBNP, and monoclonal mouse antibodies were raised to the C-terminal. Samples or NT-proBNP standards were incubated in C-terminal IgG-coated wells with the biotinylated N-terminal antibody for 24 h at 4
• C. Detection was with methylacridinium ester-labelled streptavidin on an MLX plate luminometer (Dynex Technologies). The lower limit of detection was 0.3 pmol/l. There was no cross-reactivity with ANP (atrial natriuretic peptide), BNP (B-type natriuretic peptide) or CNP (C-type natriuretic peptide).
End points
We assessed the utility of plasma copeptin and NTproBNP level for prediction of the end point of allcause mortality at 6 months. End points were obtained by reviewing the Office of National Statistics Registry and by contacting each patient. The Office of National Statistics Registry collates death certificate records. The end points were not adjudicated separately. There was a minimum of 6 months follow-up of all surviving patients.
Statistical analysis
R-2.12 [11] was used to conduct statistical analyses. Non-parametric variables are expressed as medians (range) and parametric variables as means [95 % CI (confidence interval)]. Associations between copeptin and NT-proBNP levels with demographic data, risk factors and clinical status were analysed using the MannWhitney U test and Spearman correlations. Independent predictors for time to mortality were identified using Cox proportional hazards regression, with significant univariate predictors used as covariates in multivariate analysis. Troponin, copeptin and NT-proBNP were included as continuous log 10 -transformed variables. Thus HRs (hazard ratios) refer to a 10-fold increase in levels. The impact of copeptin levels on prognosis was visualized using Kaplan-Meier curves stratified for median of plasma concentration and compared using the log rank test.
The prognostic accuracy of plasma copeptin was compared with the GRACE score by comparison of AUC (area under curve) of ROC (receiver operating characteristic) curves. The AUC of ROC curves was derived by the method of Hanley and McNeil [12] .
The GRACE score was calculated for each patient derived from clinical and demographic data using the algorithm for estimation of risk for 6 month allcause mortality [3] . The additional prognostic utility of copeptin and NT-proBNP to the GRACE score was assessed using reclassification tables with calculation of NRI (net reclassification improvement). Calculation of NRI is described in detail by Pencina et al. [13] .
Relative utility was calculated according to the method described by Baker et al. [14] . The relevant region was the risk greater than the prevalence of the end point in our cohort at 6 months. 95 % CIs were derived from 25 bootstrap replications of the original data.
The prognostic accuracy of using combinations of the GRACE score, copeptin or NT-proBNP was estimated using a logistic regression model for the outcome of total mortality at 6 months.
A two-tailed probability value of less than 0.05 was deemed to be statistically significant.
RESULTS
Patient characteristics
Consecutive patients (n = 754) were recruited, of whom 519 were male, with a median age 70 (37-97) years. No patients were lost to follow-up, and there was a minimum length of follow up of 6 months. In 6 months, 56 patients (7.4 %) had died and 49 (6.5 %) had a recurrent MI. The baseline characteristics of patients and 123 healthy controls are shown ( Table 1 ). The median time from symptom onset to blood draw in patients was 25 h 45 min. Both copeptin and NT-proBNP were significantly raised in the NSTEMI patients compared with the healthy controls ( Table 1) .
Factors associated with elevated plasma copeptin and NT-proBNP
Univariate associations between demographic and risk factors and copeptin and NT-proBNP levels in NSTEMI patients are shown (Table 2) .
Elevated copeptin levels were significantly associated with a past history of MI, HF, diabetes, Killip class >1 on admission and LVEF (left ventricular ejection fraction) <40 %, ST segment deviation at admission as well as prior prescription of aspirin, β-blockers, ACEis (angiotensinconverting enzyme inhibitors) or ARBs (angiotensin II receptor blockers). Copeptin was strongly associated with the end point of all-cause mortality at 6 months.
Copeptin level was significantly positively correlated with age and Killip class, creatinine and NT-proBNP levels in NSTEMI patients, while being inversely correlated with eGFR (Table 2 ). For comparison in healthy controls, copeptin was significantly higher in males compared with females [4.2 (2.4-28.7) pmol/l compared with 3.5 (1.5-11.8) pmol/l; P = 0.006] but not correlated with eGFR (r s = 0.05, P = 0.602) or age (r s = − 0.047, P = 0.614).
NT-proBNP levels were significantly higher in females compared with males and were further associated with a past history of MI, HF, diabetes, higher Killip class, LVEF <40 %, ST segment deviation at admission as well as previous aspirin, ACEi/ARB, β-blocker and statin use.
Higher NT-proBNP levels were significantly associated with the end points of mortality at 6 months in addition to being strongly positively correlated with age, Killip class and creatinine levels, while being inversely correlated with eGFR.
Prognostic utility of plasma copeptin and NT-proBNP
Plasma copeptin and NT-proBNP were significant predictors of all-cause mortality at 6 months in (Table 3) . Stratification by inpatient PCI (percutaneous coronary intervention) produced only minor differences in HRs (Table 3 ,* values).
Kaplan-Meier analysis
Upper median levels of copeptin (>7.9 pmol/l) at admission significantly indicated a worse outcome (P < 0.0005) (Figure 1 ).
Prognostic utility of the GRACE score, copeptin and NT-proBNP
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Statin compared with none 8. them (P = 0.016), but no significant pairwise differences (Figure 2b ). The AUC of the combination of copeptin and NT-proBNP was significantly better than that of NTproBNP alone (P = 0.020) but not copeptin alone (P = 0.285).
Comparison of relative utilities
Relative utility curves for the GRACE score, NTproBNP and copeptin are shown (Figure 3) .
Over the range of baseline risks from 0.15 to 0.6, copeptin had a consistently greater relative utility for prediction of the outcome compared with the GRACE score or NT-proBNP. When used in combination, the relative utility of the GRACE score and copeptin was consistently greater than the GRACE score and NT-proBNP as well as copeptin and NT-proBNP (Figure 4 ).
Additional prognostic utility of copeptin and NT-proBNP
We further evaluated the additional prognostic utility of copeptin and NT-proBNP when used in combination with the GRACE score compared with the GRACE score used alone as a baseline model.
Comparison of area under ROC curves
Copeptin combined with the GRACE score improved prognostic accuracy [AUC, 0.84 (0.78-0.89)] compared with the GRACE score alone [AUC, 0.81 (0.75-0.87)], but this difference did not achieve statistical significance (P = 0.079). NT-proBNP combined with the GRACE score [AUC, 0.80 (0.74-0.87)] again showed no significant increase in AUC (P = 0.871) compared with the GRACE score alone.
Difference in relative utility
At a baseline risk of 0.15, using copeptin combined with the GRACE score increased the relative utility of the GRACE score by 0. Median copeptin = 7.9 pmol/l; P < 0.0005 for difference (log rank test). 
Reclassification
Integer GRACE scores were used to assign patients into categories at low, intermediate and high risk of mortality at 6 months as per the GRACE website (http://www.outcomes-umassmed.org/GRACE/). A binary logistic regression model with GRACE score as a single continuous covariate was then used to calculate the range of probabilities associated with each category. New predicted risks of mortality with either copeptin or NT-proBNP added to the GRACE score were then calculated, which were used to reclassify individuals. Changes in classification group were then used to calculate the NRI.
For those who did not experience the end point at 6 months, the addition of copeptin improved risk classification in 100 individuals but made it worse in 44, whereas for those who did have the end point, copeptin reduced the risk classification in one individual The relevant region is the risk >0.074, the prevalence of the end point at 6 months.
while increasing the classification in two. The NRI was 13.3 % (95 % CI, 3.5-23.1) (P = 0.008), demonstrating a significant overall improvement in accuracy of risk classification compared with using the GRACE score alone (Table 4) .
NT-proBNP combined with the GRACE score failed to significantly improve risk stratification compared with using the GRACE score alone for outcome of mortality at 6 months [NRI, − 4.9 % (− 12.5 to 2.8); P = 0.211] (results not shown). 
DISCUSSION
We have shown that an elevated plasma copeptin following admission with NSTEMI is strongly associated with adverse outcomes and has independent prognostic value when included in a multivariate risk model. The present study demonstrates that copeptin could be used as a prognostic biomarker following admission with NSTEMI, which supports our previous work in a predominantly STEMI population [7] . In that previous study, plasma copeptin levels were observed to decline significantly in the days following admission, which probably accounts for the slightly higher levels observed here (7.9 pmol/l), which were sampled at admission compared with levels measured in the STEMI population (7.2 pmol/l), which were sampled at 3-5 days postadmission. This may also account for the significant association between copeptin levels and past history of MI observed here but not shown in the predominantly STEMI cohort.
Copeptin levels in the healthy controls were not only significantly less than in NSTEMI patients, but were also distributed over a narrower range, resulting in no significant correlations with either age or eGFR, in contrast with the case in NSTEMI patients. Similarly, the wider variation of copeptin levels in NSTEMI patients results in there being no significant difference in levels between men and women unlike in the healthy controls here and a previously reported healthy cohort [15] .
The inclusion of copeptin levels to a logistic regression risk model including the GRACE score produced significant incremental benefit in prognostic accuracy for mortality at 6 months, making copeptin a strong candidate for inclusion into a multimarker model, which has been suggested as the optimal approach for combining information from different risk markers [16] .
This analysis has shown that adding copeptin to the GRACE score or NT-proBNP resulted in only minor increases in ROC (Figure 2 ) performance in contrast with our previous study in a predominantly STEMI population [7] . However, ROC curves have been shown to have poor sensitivity in evaluating the incremental benefit of risk predictors [17] . Furthermore, in order for a biomarker to be clinically useful, it must show an incremental benefit over previous risk stratification methods sufficient to alter treatment decisions, which comparison of ROC curves is not able to quantify in an easily understandable manner [18] .
Thus, in the present study, we have used the newer methods of reclassification and relative utility to evaluate the potential benefit of using copeptin in addition to more established risk stratification measures, the GRACE score and NT-proBNP.
Reclassification showed that copeptin was particularly useful in down-classifying patients from higher to lower risk groups in those that did not go on to reach the end point compared with using the GRACE score alone. In contrast, NT-proBNP did not show any significant incremental benefit above the GRACE score in risk stratifying individuals into low, intermediate and highrisk groups.
Relative utility is defined as the fraction of perfect prediction that is achieved at the optimal cut-off point for the risk model, where utility refers to the sum of harms and benefits measured in the same units [19] . A relative utility of 1 indicates perfect prediction of the outcome by the prognostic model. Relative utility curves illustrate a risk model's performance over a range of risk thresholds and allow comparison with other prognostic models. The increment in relative utility produced by a new risk factor added to the baseline model can be used to calculate the test threshold, the minimum number of tests that would have to be traded for a true positive prediction. For example, a test threshold of 100 means that 100 tests would need to be performed in order to identify one person who will go on to have the end point. Our analysis showed that NT-proBNP added only marginal utility to the GRACE score, with the number of tests required to identify a true positive ranging between 1562 and 56314 for baseline risks between 15 and 40 %. In contrast, copeptin added consistently more utility, with test thresholds between 139 and 283 for the same baseline risks. This means that far fewer copeptin tests than NTproBNP would need to be performed in order to identify true positives for the outcome.
Evidence of the superior prognostic value of copeptin compared with NT-proBNP was further supported by finding that the additional relative utility and NRI of adding copeptin to a baseline model of NT-proBNP was greater than the reverse of adding NT-proBNP to a baseline model of copeptin.
Thus, in this analysis, we have shown that measurement of plasma copeptin levels adds important prognostic information to the GRACE score as well as NT-proBNP. We suggest more accurate assignment of patients into different risk groups following admission to hospital with NSTEMI would be helpful in guiding subsequent treatment decisions, although prospective clinical trials are needed to test this hypothesis.
Study limitations
The diagnostic and prognostic performance of copeptin would need to be compared against existing risk stratification tools, such as exercise testing, and would require external validation in further patient cohorts. We acknowledge the low rates of in-hospital PCI, treatment with GPIIb/IIIa (glycoprotein IIb/IIIa) inhibitors and clopidogrel, as this cohort was recruited at a period when these treatments were not so frequently used.
Conclusions
Plasma copeptin is a novel independent prognostic biomarker in patients following non-ST elevation acute coronary syndrome and improves the early prognostic accuracy of the GRACE score compared with NTproBNP.
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